{"title":"右美托咪定:尽可能安全","authors":"Deborah S. Wagner Pharm.D., Chad M. Brummett MD","doi":"10.1053/j.sane.2006.02.003","DOIUrl":null,"url":null,"abstract":"Dexmedetomidine (DMET) is an alpha-2 adrenoceptor agonist approved for short-term use as a sedative for mechanically ventilated patients. Alpha-2 adrenoceptor agonists exhibit sedative–hypnotic, analgesic, anxiolytic, and sympatholytic effects. The ability of DMET to produce a readily arousable state of moderate–deep sedation and analgesia with a lack of respiratory depression has led to an increased interest in its use. Very little published data exists on the side effects/adverse event profile of the drug, especially with high-dose prolonged infusions. In addition, the ceiling dose is not really known. This article reviews the current literature with regards to multiple organ systems and the effects of DMET.","PeriodicalId":82686,"journal":{"name":"Seminars in anesthesia","volume":"25 2","pages":"Pages 77-83"},"PeriodicalIF":0.0000,"publicationDate":"2006-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1053/j.sane.2006.02.003","citationCount":"43","resultStr":"{\"title\":\"Dexmedetomidine: as safe as safe can be\",\"authors\":\"Deborah S. Wagner Pharm.D., Chad M. Brummett MD\",\"doi\":\"10.1053/j.sane.2006.02.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Dexmedetomidine (DMET) is an alpha-2 adrenoceptor agonist approved for short-term use as a sedative for mechanically ventilated patients. Alpha-2 adrenoceptor agonists exhibit sedative–hypnotic, analgesic, anxiolytic, and sympatholytic effects. The ability of DMET to produce a readily arousable state of moderate–deep sedation and analgesia with a lack of respiratory depression has led to an increased interest in its use. Very little published data exists on the side effects/adverse event profile of the drug, especially with high-dose prolonged infusions. In addition, the ceiling dose is not really known. This article reviews the current literature with regards to multiple organ systems and the effects of DMET.\",\"PeriodicalId\":82686,\"journal\":{\"name\":\"Seminars in anesthesia\",\"volume\":\"25 2\",\"pages\":\"Pages 77-83\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2006-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1053/j.sane.2006.02.003\",\"citationCount\":\"43\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Seminars in anesthesia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0277032606000195\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in anesthesia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0277032606000195","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Dexmedetomidine (DMET) is an alpha-2 adrenoceptor agonist approved for short-term use as a sedative for mechanically ventilated patients. Alpha-2 adrenoceptor agonists exhibit sedative–hypnotic, analgesic, anxiolytic, and sympatholytic effects. The ability of DMET to produce a readily arousable state of moderate–deep sedation and analgesia with a lack of respiratory depression has led to an increased interest in its use. Very little published data exists on the side effects/adverse event profile of the drug, especially with high-dose prolonged infusions. In addition, the ceiling dose is not really known. This article reviews the current literature with regards to multiple organ systems and the effects of DMET.